Overall rank by patents
#49,501
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Phagelux holds 5 US patents across 7 technology areas, rank #49,501 of 50,000 tracked assignees.
Phagelux (canada) Inc. has been granted 5 US utility patents between 2020 and 2023, placing Phagelux (canada) Inc. at rank #49,501 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 27.2 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Phagelux (canada) Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Phagelux sits between Petvivo Holdings, Inc. (5 patents, rank #49,497) and Pharosgen Co., Ltd (5 patents, rank #49,505) - the closest US assignees by grant volume. The composite Innovation Score of 40.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Phagelux (canada) Inc.'s 27.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Phagelux (canada) Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PETVIVO HOLDINGS, INC.
5 patents
PF Loop, Inc.
5 patents
PFW AEROSPACE GMBH
5 patents
PGI INTERNATIONAL, LTD.
5 patents
PHARMA INTEGRATION S.R.L.
5 patents
PHARMANUTRA S.P.A.
5 patents
PHARMARESEARCH CO., LTD.
5 patents
PHAROSGEN CO., LTD
5 patents
PHAGELUX (CANADA) INC.
5 patents
What this shows Phagelux holds 5 patents at rank #49,501, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #49,501 in granted patent volume.
Other assignees with the most granted patents in Phagelux's primary technology class.
Phagelux's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 35% higher than 65% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
| 2023 | 2 | 40.0% |
Top 7 of 7 technology areas
Overall rank by patents
#49,501
Across all tracked assignees
40.5 out of 100
How to use this portfolio
Phagelux's 5 grants land it in the top 35% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.